A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations - Archive ouverte HAL Access content directly
Journal Articles Science Translational Medicine Year : 2020

A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

1 CNRS-UMR3569 - Virus et Immunité - Virus and immunity
2 VRI - Vaccine Research Institute
3 UPCité - Université Paris Cité
4 Découverte de pathogènes – Pathogen discovery
5 Immunologie humorale - Humoral Immunology
6 GMV-ARN (UMR_3569 / U-Pasteur_2) - Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses
7 Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology
8 Département de Virologie - Department of Virology
9 CNR - Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris]
10 Biologie des ARN et virus influenza - RNA Biology of Influenza Virus
11 Laboratoire commun Pasteur-TheraVectys
12 Virologie Moléculaire et Vaccinologie / Molecular Virology and Vaccinology
13 Laboratoire d’innovation : vaccins – Innovation lab : vaccines
14 PPR - Plateforme technologique Production et purification de protéines recombinantes – Production and Purification of Recombinant Proteins Technological Platform
15 Virologie Structurale - Structural Virology
16 IAME (UMR_S_1137 / U1137) - Infection, Anti-microbiens, Modélisation, Evolution
17 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
18 ICAReB - Investigation Clinique et d’Accès aux Ressources Biologiques (Plate-forme) - Clinical Investigation and Access to BioResources
19 Coordination du Risque Epidémique et Biologique [CHU Necker]
20 EFS - Etablissement Français du Sang
21 CHU - BREST - Hôpital de la Cavale Blanche - CHRU Brest
22 CIC 1417 - CIC Cochin Pasteur
23 Santé publique France - French National Public Health Agency [Saint-Maurice, France]
24 CESPA - Centre d'épidémiologie et de santé publique des armées [Marseille]
25 DGS - Direction Générale de la Santé
26 CNAM - Conservatoire National des Arts et Métiers [CNAM]
27 PACRI - Pasteur-Cnam Risques infectieux et émergents
28 Direction de la recherche médicale de l'Institut Pasteur
29 ENVA - École nationale vétérinaire - Alfort
François Anna
Pascal Morel
Felix Rey
  • Function : Author
  • PersonId : 1058991
Hugo Mouquet

Abstract

It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti-SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti-SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.
Fichier principal
Vignette du fichier
eabc3103.full.pdf (2.53 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

pasteur-03139185 , version 1 (11-02-2021)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Ludivine Grzelak, Sarah Temmam, Cyril Planchais, Caroline Demeret, Laura Tondeur, et al.. A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations. Science Translational Medicine, 2020, 12 (559), pp.eabc3103. ⟨10.1126/scitranslmed.abc3103⟩. ⟨pasteur-03139185⟩
143 View
317 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More